Announcements

The planned capability is designed to intercept hostile drones before they reach protected platforms, extending vehicle protection beyond armor and electronic countermeasures.

Vaxcyte, Inc. (NASDAQ: PCVX) awarded Chief Medical Officer Jodar Luis 52,632 shares at $0 per share. The award was recorded on Sep 4, 2026, and Luis’s resulting holding was 52,632 shares.

TENAX Therapeutics, Inc. (NASDAQ: TENX) released a comprehensive LEVEL clinical-trial update showing a 49% reduction in NT-proBNP, while the study’s primary endpoint did not reach statistical significance. The results update covers the company’s levosimendan development program and was made public on September 9, 2026. …

Tyra Biosciences, Inc. (NASDAQ: TYRA) identified oral dabogratinib at 60 mg once daily as a potential dose for its planned registrational adjuvant strategy in a bladder cancer population with FGFR3 alterations. SURF302 produced an overall response rate of 79%, or 11 of 14 evaluable …

UroGen Pharma Ltd. (NASDAQ: URGN) General Counsel Jason Drew Smith sold 1,519 shares at $42.54 per share on Sep. 8. His share ownership afterward stood at 53,141 shares.

UroGen Pharma Ltd. (NASDAQ: URGN) Chief Medical Officer Mark Schoenberg exercised options for 1,667 shares on Sep 7, leaving him with 60,753 shares. The next day, he sold 871 shares at $42.92 per share, after which his reported holding stood at 59,882 shares.

ProQR Therapeutics N.V. (NASDAQ: PRQR) has dosed the first participant in its AX-0811 clinical study, advancing the RNA editing candidate into testing in healthy volunteers. The study will examine safety, tolerability, pharmacokinetics and pharmacodynamic biomarkers for a potential treatment targeting cholestatic liver diseases, including …